Clinical trialsCompany release

DBV reports further VITESSE Phase 3 data on peanut patch in children aged 4-7

DBV Technologies S.A. · Thu 12 Nov 2026

DBV Technologies presented additional results from its 654-child VITESSE trial of the VIASKIN Peanut Patch at ACAAI in Phoenix, including severity of reactions and compliance.

DBV Technologies reported further results on 12 November 2026 from the Phase 3 VITESSE trial of its VIASKIN Peanut Patch. The data were presented at the ACAAI meeting in Phoenix and cover 654 peanut-allergic children aged 4 to 7.

At month 12, the patch reduced the severity of reactions during food challenges compared with placebo, according to the company. The summary available does not give numerical detail on the severity analysis.

Compliance averaged 96.1%. DBV also said that immunologic markers shifted in a way consistent with allergen immunotherapy.

The trial had already met its primary endpoint, announced earlier. The responder rate was 46.6% in the VIASKIN Peanut Patch group against 14.8% on placebo. The material provided does not describe the responder definition, the safety findings or any regulatory filing plans.

What it means for your team

  • The new analyses add secondary and supportive evidence, on reaction severity, adherence and immunologic markers, to the already reported primary result.
  • Regulatory teams tracking the programme should look for the full dataset, including safety and responder criteria, before judging the strength of the package.
  • Market-access stakeholders may find the high reported compliance of 96.1% relevant to real-world adherence discussions, though the figure comes from a trial setting.

Company's press release: DBV Technologies S.A. ↗

Article written by VigiEye from the official source (DBV Technologies S.A.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →